5-phenyl-1H-tetrazolylacetic acid | 21743-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-phenyl-1H-tetrazolylacetic acid
• 英文别名: 2-(5-phenyl-1H-1,2,3,4-tetrazol-1-yl)acetic acid；5-Phenyl-tetrazolyl-(1)-essigsaeure；5-Phenyl-1-tetrazolylessigsaeure；(5-phenyltetrazol-1-yl)-acetic acid；(5-Phenyl-tetrazol-1-yl)-essigsaeure；5-Phenyl-1-tetrazoleacetic acid；2-(5-phenyltetrazol-1-yl)acetic Acid
• CAS: 21743-58-8
• 化学式: C₉H₈N₄O₂
• 分子量: 204.188
• InChiKey: BYVHAWLFYKHSKH-UHFFFAOYSA-N

物化性质

• 沸点：
  458.3±47.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  80.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-phenyl-1H-tetrazolylacetic acid 在 五氯化磷 、 苯 作用下， 生成 (5-phenyl-tetrazol-1-yl)-acetic acid-(2-diethylamino-ethyl ester); hydrochloride
  参考文献：
  名称：

  Tetrazole Derivatives. III. Tetrazole Acid Derivatives

  摘要：

  DOI：

  10.1021/jo01113a013
• 作为产物：
  描述：

  马尿酸乙酯 在 五氯化磷 、 苯 作用下， 生成 5-phenyl-1H-tetrazolylacetic acid
  参考文献：
  名称：

  Studies in Tetrazole Chemistry. IV. Tetrazolylacetic Acids and Esters¹

  摘要：

  DOI：

  10.1021/jo01109a013

文献信息

• Ramoplanin derivatives possessing antibacterial activity
  申请人：Raju G. Bore

  公开号：US20060211603A1

  公开（公告）日：2006-09-21

  Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型拉莫普兰衍生物已被披露。这些拉莫普兰衍生物表现出抗菌活性。由于本发明的化合物对革兰氏阳性细菌表现出强效活性，它们是有用的抗微生物药剂。该化合物的合成方法和使用方法也已被披露。
• Tetrazoleacetic acid derivatives and method of aldose reductase
  申请人：Wakamoto Pharmaceutical Co., Ltd.

  公开号：US05262433A1

  公开（公告）日：1993-11-16

  A tetrazoleacetic acid derivative represented by the following general formula I: ##STR1## wherein in the formula I, R represents a hydrogen atom or a lower alkyl group; A is an alkylene group having 2 to 5 carbon atoms; Ar is selected from the group consisting of a phenyl group, a naphthyl group, a furyl group, a thienyl group, a benzofuryl group, and a benzothienyl group; wherein the Ar may be substituted with a lower alkyl group, a lower alkoxy group, a halogen atom, a lower haloalkyl group, an alkylthio group and an alkylsulfonylamino group shows excellent aldose reductase inhibitory activity, and is quite effective as an essential component of a preventive medicine and/or remedy for diabetic complications.

  以下是通式I所代表的四唑乙酸衍生物：##STR1## 其中，在通式I中，R代表氢原子或较低的烷基；A是具有2至5个碳原子的烷基；Ar被选择为由苯基，萘基，呋喃基，噻吩基，苯并呋喃基和苯并噻吩基组成的群体，其中Ar可以被较低的烷基，较低的烷氧基，卤原子，较低的卤代烷基，烷硫基和烷基磺酰胺基所取代，表现出优异的醛糖还原酶抑制活性，并且作为预防糖尿病并发症的必要组分和/或药物疗法非常有效。
• Lantana plant named ‘Baloomwite’
  申请人：Ball Horticultural Company

  公开号：USPP035281P2

  公开（公告）日：2023-07-25

  A new and distinct cultivar of Lantana plant named ‘Baloomwite’, characterized by its white-colored inflorescences, dark green-colored foliage, and moderately vigorous, upright, mounded to rounded growth habit, is disclosed.

  本发明揭示了一种名为“Baloomwite”的新品种的篮花植物，其特征是其白色花序，深绿色叶片，和中等生长势、直立、圆锥形生长习性。
• Tetrazole derivatives and aldose reductase inhibition therewith
  申请人：Wakamoto Pharmaceutical Co., Ltd.

  公开号：US05055481A1

  公开（公告）日：1991-10-08

  The present invention relates to an aldose reductase inhibitor having the following formula: ##STR1## R.sub.1 is a hydrogen atom or --A--COOR.sub.5 (A is an alkylene group having 1 to 4 carbon atoms and R.sub.5 is a hydrogen atom or a lower alkyl group), and R.sub.2, R.sub.3 and R.sub.4 are the same as or different from each other and selected from the group consisting of a hydrogen atom, a hydroxy group, a halogen atom, a carboxyl group, an alkyl group, an amide group, an amino group, an alkoxy group, an aryl group, an aryloxy group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, a nitro group, --NHCOCOOR.sub.6 (R.sub.6 is a hydrogen atom or a lower alkyl group), a mono- or dialkylaminosulfonyl group, and a residual group having the following formula: ##STR2## (A and R.sub.5 are the same as in the above). The compounds defined in the above are excellent in aldose reductase inhibitory activity and low in toxicity. Therefore, those compounds are useful as a preventive agent and/or a remedy for diabetic complications such as neuropathy, retinopathy, nephropathy, cataracts and keratopathy.

  本发明涉及一种醛还原酶抑制剂，其具有以下式子：##STR1##其中，R.sub.1是氢原子或--A--COOR.sub.5（A是具有1至4个碳原子的烷基基团，R.sub.5是氢原子或较低的烷基基团），而R.sub.2、R.sub.3和R.sub.4相同或不同，选自以下组中的一种：氢原子、羟基、卤原子、羧基、烷基、酰胺基、氨基、烷氧基、芳基、芳氧基、烷硫基、烷基亚硫酰基、烷基磺酰基、硝基、--NHCOCOOR.sub.6（R.sub.6是氢原子或较低的烷基基团）、单烷基或双烷基氨基磺酰基，以及以下式子的残基：##STR2##（其中，A和R.sub.5与上述相同）。上述定义的化合物具有出色的醛还原酶抑制活性，并且毒性低。因此，这些化合物可用作糖尿病并发症（如神经病变、视网膜病变、肾病、白内障和角膜病变）的预防剂和/或治疗剂。
• Discovery of a Dual SENP1 and SENP2 Inhibitor
  作者：Michael Brand、Elias Benjamin Bommeli、Marc Rütimann、Urs Lindenmann、Rainer Riedl

  DOI：10.3390/ijms232012085

  日期：——

  SUMOylation is a reversible post–translational modification (PTM) involving covalent attachment of small ubiquitin-related modifier (SUMO) proteins to substrate proteins. Dysregulation of SUMOylation and deSUMOylation results in cellular malfunction and is linked to various diseases, such as cancer. Sentrin-specific proteases (SENPs) were identified for the maturation of SUMOs and the deconjugation of SUMOs from their substrate proteins. Hence, this is a promising target tackling the dysregulation of the SUMOylation process. Herein, we report the discovery of a novel protein-protein interaction (PPI) inhibitor for SENP1-SUMO1 by virtual screening and subsequent medicinal chemistry optimization of the hit molecule. The optimized inhibitor ZHAWOC8697 showed IC50 values of 8.6 μM against SENP1 and 2.3 μM against SENP2. With a photo affinity probe the SENP target was validated. This novel SENP inhibitor represents a new valuable tool for the study of SUMOylation processes and the SENP-associated development of small molecule-based treatment options.

  SUMO酰化是一种可逆的翻译后修饰（PTM），涉及到小泛素相关修饰蛋白（SUMO）与底物蛋白的共价连接。SUMOylation 和 deSUMOylation 的失调会导致细胞功能紊乱，并与癌症等多种疾病有关。研究发现，Sentrin 特异性蛋白酶（SENPs）能使 SUMOs 成熟，并将 SUMOs 从其底物蛋白中分离出来。因此，这是解决 SUMOylation 过程失调的一个很有前景的靶点。在此，我们报告了通过虚拟筛选和随后对命中分子的药物化学优化，发现了一种新型的 SENP1-SUMO1 蛋白-蛋白相互作用（PPI）抑制剂。优化后的抑制剂 ZHAWOC8697 对 SENP1 的 IC50 值为 8.6 μM，对 SENP2 的 IC50 值为 2.3 μM。通过光亲和探针，SENP 的靶点得到了验证。这种新型 SENP 抑制剂是研究 SUMOylation 过程和开发与 SENP 相关的小分子治疗方案的新的宝贵工具。